Vaxart, Inc. to Post Q1 2024 Earnings of ($0.18) Per Share, B. Riley Forecasts (NASDAQ:VXRT)

Vaxart, Inc. (NASDAQ:VXRTFree Report) – Equities researchers at B. Riley issued their Q1 2024 EPS estimates for shares of Vaxart in a research note issued on Wednesday, March 20th. B. Riley analyst M. Mamtani forecasts that the biotechnology company will post earnings per share of ($0.18) for the quarter. B. Riley has a “Buy” rating and a $2.00 price target on the stock. The consensus estimate for Vaxart’s current full-year earnings is ($0.48) per share. B. Riley also issued estimates for Vaxart’s Q3 2024 earnings at ($0.09) EPS, Q4 2024 earnings at $0.04 EPS, FY2024 earnings at ($0.32) EPS, FY2025 earnings at ($0.19) EPS and FY2026 earnings at ($0.06) EPS.

Vaxart (NASDAQ:VXRTGet Free Report) last posted its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.03. The company had revenue of $3.25 million for the quarter, compared to analyst estimates of $0.45 million. Vaxart had a negative net margin of 1,117.56% and a negative return on equity of 108.45%.

Vaxart Price Performance

NASDAQ VXRT opened at $1.26 on Friday. The firm has a market capitalization of $219.06 million, a price-to-earnings ratio of -2.17 and a beta of 0.44. The company’s fifty day moving average is $1.11 and its two-hundred day moving average is $0.83. Vaxart has a 52-week low of $0.53 and a 52-week high of $1.59.

Institutional Trading of Vaxart

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in Vaxart in the 4th quarter worth $25,000. Beacon Capital Management LLC lifted its holdings in shares of Vaxart by 369.9% during the 4th quarter. Beacon Capital Management LLC now owns 50,814 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 40,000 shares during the period. Schonfeld Strategic Advisors LLC bought a new position in shares of Vaxart during the 2nd quarter worth about $29,000. Two Sigma Advisers LP bought a new position in shares of Vaxart during the 3rd quarter worth about $34,000. Finally, Centiva Capital LP bought a new position in shares of Vaxart during the 4th quarter worth about $37,000. 19.04% of the stock is currently owned by institutional investors and hedge funds.

About Vaxart

(Get Free Report)

Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia.

See Also

Earnings History and Estimates for Vaxart (NASDAQ:VXRT)

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.